Quantcast

Latest Prostate cancer Stories

2014-10-17 00:21:14

SAN DIEGO, Oct. 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical prostatectomy. An LCD is a decision by Medicare contractors to cover an item or service. Decipher is the only genomic test for prostate...

2014-10-16 08:30:32

NEW YORK, Oct. 16, 2014 /PRNewswire/ -- Analyst Report by Small Cap IR. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - According to the World Health Organization, over 14 million new cases of cancer are reported each year, and cancer cases are expected to surge 57% worldwide over the next 20 years. The fastest growing hospital treatment in the United States to treat this disease is Hematopoietic Stem Cell Transplantation; the transplantation of multipotent hematopoietic stem cells...

2014-10-14 12:30:37

OWINGS MILLS, Md., Oct. 14, 2014 /PRNewswire-USNewswire/ -- Chesapeake Urology Associates ("Chesapeake"), continually on the forefront of clinical and technological innovation, offers a state-of-the-art prostate cancer diagnostic, which "fuses" detailed MRI scans with live, real-time ultrasound images of the prostate. This groundbreaking biopsy system provides Chesapeake urologists with the capability to pinpoint tumors within the prostate gland, leading to more targeted treatment planning...

2014-10-14 12:29:42

WASHINGTON, Oct. 14, 2014 /PRNewswire-USNewswire/ -- ZERO - The End of Prostate Cancer recently awarded the Jim Lafferty Memorial Research Grant in the amount of $45,000 to Peter Carroll, M.D., M.P.H., of UC San Francisco for the purpose of researching new and improved methods for early detection of prostate cancer. The grant is part of the ZERO Cancer Research Fund, charged with supporting innovative, high-reward research that offers the best return on investment for patients and...

2014-10-14 08:34:17

First Patient Has Begun Treatment Process; Additional Patients Being Assessed; Waiting List Established BETHESDA, Md., Oct. 14, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the DCVax-L Hospital Exemption Program that was approved by the German regulatory authority earlier this year is now under way. The first patient with Glioblastoma...

2014-10-09 08:27:36

ProMark(TM) Validated to Predict Disease Aggressiveness and Empower Informed Treatment Decisions CAMBRIDGE, Mass., Oct. 9, 2014 /PRNewswire/ -- Metamark announced today the nationwide availability of ProMark(TM), the first-of-its-kind protein-based biopsy test designed to improve the accuracy of prognosis for men diagnosed with prostate cancer. For the 205,000 men annually with indeterminate Gleason scores (3+3 and 3+4), ProMark can help identify aggressiveness of the disease....

2014-10-09 08:27:33

SAN ANTONIO, Texas, October 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that patient enrollment has been completed in the company's Phase II clinical trial in patients with liver cancer (hepatocellular carcinoma). Formal results of the study are expected to be available during the first quarter of 2015. "We are grateful to the trial investigators for their efforts, as well as the...

2014-10-07 23:05:16

With a device necessary for many medical conditions and surgeries, manufacturers of urinary catheters have a safe and stable source of revenue that can withstand the steepest of economic downturns, reports iData Research Vancouver, BC (PRWEB) October 07, 2014 According to in-depth reports from iData Research, the leading global authority on medical device market research, the combined U.S. and European markets for urological devices was valued at almost US$4.7 billion in 2013, with both...

2014-10-07 08:28:45

PETACH TIKVA, Israel, Oct. 7, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the Company's CEO, Dr. Pnina Fishman, will co-chair the Cancer Therapeutics session of the 19th World Congress on Advances in Oncology. The conference will take place in Athens, Greece, from October 9-11, 2014. In addition to co-chairing...

2014-10-03 23:00:25

SonaCare Medical FDA Panel Review for Its Sonablate® 450 Prostate Ablation System CHARLOTTE, NC (PRWEB) October 03, 2014 FRIDAY, OCTOBER 3, 2014 SonaCare Medical, LLC, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, announced that the Gastroenterology and Urology Device Panel met on Wednesday October 1st with representatives from the FDA and SonaCare Medical to review and vote on recommendations for the interim analysis of SonaCare Medical’s...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related